Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03844750
Recruitment Status : Recruiting
First Posted : February 18, 2019
Last Update Posted : April 28, 2022
Sponsor:
Collaborators:
Merck Sharp & Dohme LLC
MedPacto, Inc.
Information provided by (Responsible Party):
Chloe Atreya, MD, PhD, University of California, San Francisco

Brief Summary:
This phase II trials studies how well pembrolizumab and vactosertib work after standard of care chemotherapy in patients with colorectal cancer that has spread to the liver that can be removed by surgery (resectable hepatic metastases). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vactosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and vactosertib after standard of care chemotherapy, but before liver metastases surgery, may help shrink the cancer prior to surgery. This study also investigates pembrolizumab and vactosertib after liver metastases surgery, decrease the risk of the cancer recurring (coming back).

Condition or disease Intervention/treatment Phase
Metastatic Malignant Neoplasm in the Liver Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Procedure: Hepatectomy Biological: Pembrolizumab Drug: Vactosertib Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases
Actual Study Start Date : July 22, 2019
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment (vactosertib, pembrolizumab, surgery)

Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks).

Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days per week) will be administered for up to eight 6-week cycles

Procedure: Hepatectomy
Undergo liver resection.
Other Name: Liver Resection

Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • Lambrolizumab
  • MK-3475
  • SCH 900475

Drug: Vactosertib
Given orally once a day (QD) for cycle 1, and twice a day (BID) for cycle 2 and beyond
Other Name: EW-7197




Primary Outcome Measures :
  1. Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens. [ Time Frame: Up to 2 years ]
    Tumor-infiltrating immune cells (TIICs) will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab treatment tumor specimens. The proportion of patients with a >= 2-fold increase (from pre- to post-treatment) in the number of TIICs per unit area (5 high power fields) will be calculated.


Secondary Outcome Measures :
  1. Proportion of participants with treatment-related, adverse events [ Time Frame: Up to 2 years ]
    Adverse events (AEs) will be analyzed including but not limited to all AEs, serious (S)AEs, and fatal AEs using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5 for classification. Due to the potential for late toxicities from pembrolizumab, patients will be followed for 1 year after their last dose of pembrolizumab.

  2. Proportion of participants with events of clinical interest (ECIs) [ Time Frame: Up to 2 years ]
    Specific immune-related AEs (irAEs) will be collected and designated as immune-related events of clinical interest (ECIs). The study will use descriptive statistics to report on the safety/toxicity. Due to the potential for late toxicities from pembrolizumab, patients will be followed for 1 year after their last dose of pembrolizumab

  3. Proportion of participants with perioperative complications [ Time Frame: Up to 1 month ]
    The proportion of participants with reported perioperative complications related to study treatment will be reported.

  4. Proportion of participants with an R0 resection [ Time Frame: Up to 1 month ]
    Participants who undergo surgical resection of liver metastases will be evaluable and the proportion of participants requiring an R0 resection will be reported

  5. Pathologic response rate [ Time Frame: Up to 1 year ]
    Participants who undergo surgical resection of liver metastases will be evaluable and the proportion of participants with a pathological tumor response will be reported

  6. Objective response rate (ORR) [ Time Frame: Up to 1 year ]
    Participants with a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be reported.

  7. Median Relapse-free survival (RFS) per RECIST 1.1 [ Time Frame: Up to 2 years ]
    The time from objective response to progression or death will be used to determine relapse-free survival.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Has histologically or cytologically confirmed CRC with liver metastases. In addition to liver metastases, extrahepatic metastases (e.g. pulmonary metastases) may be permitted if all other eligibility criteria are met. Patients are permitted to have primary tumor in situ (Neoadjuvant Arm only).
  2. Has received previous oxaliplatin-based chemotherapy.

    1. FOLFOX or capecitabine combined with oxaliplatin (CapeOx) does not need to be a direct lead-in to this study.
    2. If chemotherapy is a direct lead-in to this study, concurrent mAb therapy (bevacizumab, cetuximab, or panitumumab) is acceptable, however the antibody must be omitted from the final cycle of chemotherapy prior to pembrolizumab.
  3. Is an appropriate candidate to undergo liver biopsy and resection (+/-ablation) of liver metastases according to the interpretation of the Multidisciplinary Gastrointestinal (GI) Tumor Board (Neoadjuvant Arm Only).
  4. Is willing and able to provide written informed consent/assent for the trial. The patient may also provide consent for Future Biomedical Research. However, the patient may participate in the main trial without participating in Future Biomedical Research.
  5. Is >=18 years of age on day of signing informed consent.
  6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions (Neoadjuvant Arm Only).
  7. Is willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained after last dose of standard of care lead-in chemotherapy [if applicable] and within 28 days prior to first dose of pembrolizumab (Neoadjuvant Arm Only).
  8. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  9. Has adequate organ function as defined below. All screening labs should be performed within 10 days of treatment initiation.

    • Absolute neutrophil count (ANC) >= 1,500/microliter (uL) (within 10 days of treatment initiation).
    • Platelets >= 100,000/uL (within 10 days of treatment initiation).
    • Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).
    • Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl)) >= 60 mL/min for patient with creatinine levels > 1.5 x institutional ULN (within 10 days of treatment initiation).

      • Creatinine clearance should be calculated per institutional standard.
    • Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 ULN (within 10 days of treatment initiation).
    • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) =< 2.5 x ULN (within 10 days of treatment initiation).
    • Albumin >= 2.5 mg/dL (within 10 days of treatment initiation).
    • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation).
    • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation).
  10. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (day 1). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  11. Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.
  12. Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

    • Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
  13. Have locally confirmed microsatellite stable (MSS) or Mismatch repair proficient (pMMR) Colorectal cancer (CRC). MSS is defined as 0-1 allelic shifts among 3-5 tumor microsatellite loci using a Polymerase chain reaction (PCR)-based assay. pMMR is defined as presence of protein expression of 4 DNA mismatch repair (MMR) enzymes (MLH1, MSH2, MSH6 and PMS2) by immunohistochemistry.

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

    • Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since the last dose of the previous investigational agent or device use.
  2. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  3. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
  4. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  5. Has active hepatitis B (defined as hepatitis B surface antigen (HBsAg) reactive) or active hepatitis C virus (HCV) (defined as HCV RNA [qualitative] is detected) infection.
  6. Has received prior anti-cancer monoclonal antibody (mAb), systemic anticancer therapy other than FOLFOX (including investigational agents), targeted small molecule therapy, or radiation therapy within 14 days prior to the first dose of study treatment (day 1).

    • Note: Patients must have recovered from all adverse events (AEs) due to a previous therapies to =< grade 1 or baseline. Patients with grade 2 neuropathy or alopecia are eligible. If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
  7. Has received FOLFOX less than 7 days prior to the first dose of study treatment (day 1). Has not recovered (i.e., =< grade 1 or at baseline) from AEs due to FOLFOX chemotherapy.

    • Note: Patients with =< grade 2 neuropathy or alopecia are exceptions to this criterion and may qualify for the study.
  8. Has not recovered adequately from toxicity or complications of a surgery or other procedure, per the assessment of the treating investigator.
  9. Has received liver-directed therapy such as radiotherapy or yttrium-90 in the past year.
  10. Has a known additional malignancy that is progressing or has required active treatment within 5 years prior.

    • Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  11. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression by imaging for at least 4 weeks by repeat imaging [repeat imaging should be performed during the study screening]), clinically stable, and without requirement of steroid treatment for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  12. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
  13. Has an active infection requiring systemic therapy.
  14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator. Anticoagulation that cannot be safely held to perform the liver biopsy is an example of a contraindication to participation.
  15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  16. Has received any prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137)).
  17. Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or to any of pembrolizumab's excipients.
  18. Has received a live or live-attenuated vaccine within 30 days prior to first dose of the trial drug. Administration of killed vaccines are allowed.
  19. Has inferior vena cava/cardiac involvement based on imaging.
  20. Has had encephalopathy in the last 6 months. Those patients on rifaximin or lactulose to control their encephalopathy are not allowed.
  21. Has had a solid organ or hematologic transplant.
  22. Has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions (including therapeutic thora- or paracentesis) is eligible.
  23. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III/IV), uncontrolled hypertension (>=150/90mmHg), unstable angina pectoris or myocardial infarction (≤ 6 months prior to screening), uncontrolled cardiac arrhythmia, clinically significant cardiac valvulopathy requiting treatment, active interstitial lung disease, or serious chronic gastrointestinal conditions associated with diarrhea.
  24. QT interval corrected for heart rate using Fridericia's formula (QTcF) >=450 ms in male and >=470 ms in female calculated from 12-lead ECGs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03844750


Contacts
Layout table for location contacts
Contact: UCSF HDFCCC Cancer Immunotherapy Program (CIP) (877) 827-3222 HDFCCC.CIP@ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: UCSF HDFCCC Cancer Immunotherapy Program    877-827-3222    HDFCCC.CIP@ucsf.edu   
Contact       cancertrials@ucsf.edu   
Principal Investigator: Chloe E. Atreya, MD, PhD         
Sponsors and Collaborators
Chloe Atreya, MD, PhD
Merck Sharp & Dohme LLC
MedPacto, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Chloe Atreya, MD, Ph.D. University of California, San Francisco
Layout table for additonal information
Responsible Party: Chloe Atreya, MD, PhD, Principal Investigator, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03844750    
Other Study ID Numbers: 187015
NCI-2018-03165 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: February 18, 2019    Key Record Dates
Last Update Posted: April 28, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Chloe Atreya, MD, PhD, University of California, San Francisco:
Resectable hepatic metastases
Surgery
Immunotherapy
Adjuvant Treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents